Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma

Pediatr Blood Cancer. 2021 Mar;68(3):e28753. doi: 10.1002/pbc.28753. Epub 2020 Oct 19.

Authors

Krupesh Patel¹, Jeffrey Allen¹, David Zagzag², Jeffrey Wisoff³, Alireza Radmanesh⁴, Tatyana Gindin², Theodore Nicolaides¹

Affiliations

¹ Department of Pediatrics, NYU Langone Health, New York, New York.
² Department of Pathology, NYU Langone Health, New York, New York.
³ Department of Neurosurgery, NYU Langone Health, New York, New York.
⁴ Department of Radiology, NYU Langone Health, New York, New York.

PMID: 33073916
DOI: 10.1002/pbc.28753

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Benzimidazoles / therapeutic use*
Craniopharyngioma / drug therapy*
Craniopharyngioma / metabolism
Craniopharyngioma / pathology
Female
Humans
MAP Kinase Kinase 1 / antagonists & inhibitors*
Magnetic Resonance Imaging / methods*
Pituitary Neoplasms / drug therapy*
Pituitary Neoplasms / metabolism
Pituitary Neoplasms / pathology
Protein Kinase Inhibitors
Wnt1 Protein / metabolism*

Substances

Benzimidazoles
Protein Kinase Inhibitors
WNT1 protein, human
Wnt1 Protein
binimetinib
MAP Kinase Kinase 1
MAP2K1 protein, human